Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31204043 | 1.00 | GSK3B (0.49) | GSK3BENPP2CLK4IRAK4FBP1 | |
| SCHEMBL11423965 | 1.00 | GSK3B (0.49) | GSK3BENPP2CLK4IRAK4FBP1 | |
| SCHEMBL4397349 | 1.00 | GSK3B (0.49) | GSK3BENPP2CLK4IRAK4FBP1 | |
| SCHEMBL15338690 | 0.81 | CYP1A1 (0.37) | GSK3B | |
| SCHEMBL10761499 | 0.78 | GSK3B (0.53) | GSK3BENPP2CLK4IRAK4GRM5 | |
| SCHEMBL10761496 | 0.78 | GSK3B (0.53) | GSK3BENPP2CLK4IRAK4GRM5 | |
| SCHEMBL1421297 | 0.78 | GSK3B (0.49) | GSK3BENPP2CLK4IRAK4GRM5 | |
| SCHEMBL16572029 | 0.78 | GSK3B (0.49) | GSK3BENPP2CLK4IRAK4GRM5 | |
| SCHEMBL17134105 | 0.78 | GSK3B (0.49) | GSK3BENPP2CLK4IRAK4GRM5 | |
| SCHEMBL1421298 | 0.78 | GSK3B (0.49) | GSK3BENPP2CLK4IRAK4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522608-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546602-A | Pyrrolidone derivatives as inhibitors of nfkb-induced kinase | 詹森药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-116535399-B | 3-hydroxy-5- (isoxazol-5-yl) pyridine formyl glycine compound, preparation method, pharmaceutical composition and application | 中国药科大学 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023217906-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| CN-116535399-A | 3-hydroxy-5- (isoxazol-5-yl) pyridine formyl glycine compound, preparation method, pharmaceutical composition and application | 中国药科大学 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023142214-A1 | 3-HYDROXY-5-(ISOXAZOL-5-YL) PYRIDINE FORMYLGLYCINE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 中国药科大学 | 2023-08-03 | — | — | WO | disclosed |
| US-11028072-B2 | 2,4-diamino-6-ethylpyrimidine derivatives with antimalarial activities against Plasmodium falciparum | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2021-06-08 | — | — | US | disclosed |
| US-20200239445-A1 | 2,4-DIAMINO-6-ETHYLPYRIMIDINE DERIVATIVES WITH ANTIMALARIAL ACTIVITIES AGAINST PLASMODIUM FALCIPARUM | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2020-07-30 | — | — | US | disclosed |
| WO-2017052479-A1 | 2,4-DIAMINO-6-ETHYLPYRIMIDINE DERIVATIVES WITH ANTIMALARIAL ACTIVITIES AGAINST PLASMODIUM FALCIPARUM | NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY (TH) | 2017-03-30 | — | — | WO | disclosed |
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1919911-A1 | BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007021574-A1 | BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20060166906-A1 | 6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance | ABBOTT LABORATORIES | 2006-07-27 | — | — | US | disclosed |
| EP-1328534-A2 | 6-O-SUBSTITUTED ERYTHROMYCIN DERIVATIVES HAVING IMPROVED GASTROINTESTINAL TOLERANCE | Abbott Laboratories (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032919-A2 | 6-O-SUBSTITUTED ERYTHROMYCIN DERIVATIVES HAVING IMPROVED GASTROINTESTINAL TOLERANCE | ABBOTT LABORATORIES (US) | 2002-04-25 | — | — | WO | disclosed |
| US-4261728-A | PREEMERGENT ACTIVITY | MONSANTO COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
| US-4187099-A | 3-Aryl-4-isothiazolecarboxylic acid and 3-aryl-4-isoxazolecarboxylic acid derivatives and their use as herbicides | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4144047-A | SOYBEANS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | GRM5, GRM1, GRIN1 | GSK3B 3401/4885ENPP2 1475/4885CLK4 2886/4885 |
| US-20060166906-A1 | 6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance | CYP2D6, CYP2B6, UGT1A6 | GSK3B 3734/4885ENPP2 3006/4885CLK4 4702/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | GSK3B 522/4885ENPP2 1143/4885CLK4 1923/4885 |
| US-11028072-B2 | 2,4-diamino-6-ethylpyrimidine derivatives with antimalarial activities against Plasmodium falciparum | DHFR, DPYD, DHODH | GSK3B 4432/4885ENPP2 653/4885CLK4 3672/4885 |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | GRM5, GRM1, GRIN1 | GSK3B 3401/4885ENPP2 1475/4885CLK4 2886/4885 |
| US-20200239445-A1 | 2,4-DIAMINO-6-ETHYLPYRIMIDINE DERIVATIVES WITH ANTIMALARIAL ACTIVITIES AGAINST PLASMODIUM FALCIPARUM | DHFR, DPYD, DHODH | GSK3B 4432/4885ENPP2 653/4885CLK4 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.